Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD 371 in Healthy Subjects

Type II Diabetes Mellitus Clinical Trial

— CKD-371  

Official title:

An Open Label, Randomized, Single Dose Crossover Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD 371 in Healthy Subjects

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05544214
• Other study ID #: A127_01BE2206
• Status: Completed
• Phase: Phase 1
• Start date: October 21, 2022
• Est. completion date: November 17, 2022

Study information

• Verified date: September 2022
• Source: Chong Kun Dang Pharmaceutical
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is an open-label, randomized, single dose, crossover study to evaluate the pharmacokinetics, safety and tolerability of CKD-388 in healthy subjects

Description:

To healthy 32 subjects, following treatments are administered dosing in each period and wash-out period is a minimum of 7 days. Reference drug: D745, D759 / Test drug: CKD-371 Pharmacokinetic blood samples are collected up to 48hrs. The pharmacokinetic characteristics and safety are assessed.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 32
• Est. completion date: November 17, 2022
• Est. primary completion date: November 14, 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 19 Years to 45 Years

Eligibility

Inclusion Criteria:

1. Healthy adults volunteers aged between 19 and 45 years old at the time of screening

2. Weight =50kg, with calculated body mass index (BMI) of 18.0 to 29.9 kg/m2 at the time of screening

3. Individuals who voluntarily decide to participate and agree to comply with the cautions after fully understand the detailed description of this clinical trial

Exclusion Criteria:

1. Those with clinically significant diseases or history in cardiovascular system, respiratory system, liver, kidney, hematological, gastrointestinal, endocrine system, immune system, skin system, mental/nervous system, etc

2. Those who have symptoms of acute disease within 28 days of the the first dose of the investigational product

3. Those who with a history of influencing drug absorption, distribution, metabolism, and excretion

4. Those who have a hypersensitivity reaction or a history of clinically significant hypersensitivity reaction or a history of drug abuse inculding SGLT2 inhibitor class component or DPP 4 inhibitor class or same class component drugs containing ingredients

5. Those with clinically significant active chronic disease

6. Those with genetic problems such as galactose intolerance, Lapp lactase deficiency or glucose galactose malabsorption

7. A person who has had one or more of the following results in screening tests including re-examination

• AST, ALT > UNL (upper normal limit) x 2.5
• Fasting glucose < 70 mg/dL
• Calculated by Cockcroft Gault formula Creatinine clearance is 75mL/min or less (Cockcroft Gault GFR = (140 age) * (Wt in kg) / (72 * Cr))
• QTc > 470 msec as a result of ECG
• Urine-hCG test is positive(if it is limited to female subjects)

8. Those who test positive for HBs Ag, HCV Ab, HIV Ab, or VDRL

9. Those who have taken prescription medicine (ETCs), including prescription drugs, within 14 days of the first dose

10. Those who have taken over-the-counter medicines (OTC) including herbal medicines within 7 days of the first dose

11. Clinically significant allergic diseases, mild allergic rhinitis that do not require medication, and allergic dermatitis can be selected

12. Those who cannot eat the standard meal provided by the institution

13. Those who donated whole blood within 60 days prior to the first dose or donated component blood within 20 days

14. Those who received a blood transfusion within 30 days prior to the first dose

15. Those who have participated in other clinical studies or bioequivalence studies within 6 months of the first dose and administered the investigational drug

16. Those who had taken any drug known as a strong inducer or inhibitor of drug-metabolizing enzymes within 30 days prior to the first dose of the investigational product

17. Those who have continuously consumed grapefruit juice or caffeine > 5 cups a day, or cannot refrain from intake during hospitalization

18. Consistently drinking alcohol > 30 days or unable to abstain from alcohol during hospitalization

19. Excessive smokers > 20 cigarettes non-daily or unable to quit smoking during hospitalization

20. Pregnant or childbearing potential and lactating women

21. Those who consent to the use of reliable contraception(contraceptive methods other than hormones: use of condoms, intrauterine devices (IUD, IUS), tubal ligation, cervical cap, contraceptive diaphragm, etc.) during the clinical trial and not to donate sperm until 2 month after the last administration of investigational product

22. Clinical laboratory test results and other reasons eg, a person who does not respond to requests and instructions, or who judges the investigator to be inappropriate to participate in the clinical trial with a non-cooperative attitude

Related Conditions & MeSH terms

• Diabetes Mellitus, Type 2
• Type II Diabetes Mellitus

Intervention

Drug:
• CKD-371
PO

Locations

Country	Name	City	State
Korea, Republic of	Korea University Anam Hospital	Seoul

Sponsors (1)

Lead Sponsor	Collaborator
Chong Kun Dang Pharmaceutical

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	AUCt of CKD-371, D745+D759	Area under the CKD-371, D745+D759 concentration in blood-time curve from zero to final	Pre-dose(0hr), post-dose 0.33, 0.67, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48hr
Primary	Cmax of CKD-371, D745+D759	The maximum CKD-388/D418 concentration in blood sampling time	Pre-dose(0hr), post-dose 0.33, 0.67, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48hr